(Q39691306)

14 September 2017

Cell cycle arrest and apoptosis in TP53 subtypes of bladder carcinoma cell lines treated with cisplatin and gemcitabine (English)

1 reference

14 September 2017

1 reference

1 reference

Glenda Nicioli da Silva

1

0 references

Elza T Sakamoto-Hojo

object named as

Elza Tiemi Sakamoto-Hojo

5

0 references

author name string

João Paulo de Castro Marcondes

2

1 reference

14 September 2017

Elaine Aparecida de Camargo

3

1 reference

14 September 2017

Geraldo Aleixo da Silva Passos Júnior

4

1 reference

14 September 2017

Daisy Maria Fávero Salvadori

6

1 reference

14 September 2017

language of work or name

1 reference

1 July 2010

1 reference

Experimental Biology and Medicine

14 September 2017

1 reference

14 September 2017

235

1 reference

14 September 2017

814-824

1 reference

14 September 2017

7

1 reference

Bladder cancer: epidemiology, staging and grading, and diagnosis.

14 September 2017

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.009322

Systemic chemotherapy in locally advanced and/or metastatic bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.009322

Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.009322

Molecular alterations associated with bladder cancer initiation and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.009322

The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.009322

An updated review of the literature: risk factors for bladder cancer with focus on occupational exposures

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.009322

Advanced bladder cancer: status of first-line chemotherapy and the search for active agents in the second-line setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.009322

Gemcitabine in the treatment of advanced transitional cell carcinoma of the urothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.009322

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.009322

Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.009322

Cisplatin: mode of cytotoxic action and molecular basis of resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.009322

Gemcitabine in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.009322

Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.009322

Nucleoside analogues: mechanisms of drug resistance and reversal strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.009322

Role of gemcitabine in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.009322

p53 and chemosensitivity in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.009322

Wild-type p53 in cancer cells: when a guardian turns into a blackguard

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.009322

Predicting response to cancer chemotherapy: the role of p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.009322

Mechanisms of resistance to cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.009322

DNA microarrays identification of primary and secondary target genes regulated by p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.009322

Cisplatin-induced growth arrest of head and neck cancer cells correlates with increased expression of p16 and p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.009322

Mutation of p53 in head and neck squamous cell carcinoma correlates with Bcl-2 expression and increased susceptibility to cisplatin-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.009322

Clinical evaluation of p53 mutations in urothelial carcinoma by IHC and FASAY.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.009322

The role of p53 in gemcitabine-mediated cytotoxicity and radiosensitization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.009322

Gemcitabine-induced apoptosis in a drug-resistant mouse leukemia L1210 cell line that does not express p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.009322

Preclinical evaluation of a radiosensitizing effect of gemcitabine in p53 mutant and p53 wild type bladder cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.009322

Human bladder carcinoma cell lines as indicators of oncogenic change relevant to urothelial neoplastic progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.009322

Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: Direct STAT3 inhibition induces apoptosis in prostate cancer lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.009322

Ellipticine induces apoptosis through p53-dependent pathway in human hepatocellular carcinoma HepG2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.009322

Overexpression of COX-2 in human osteosarcoma cells decreases proliferation and increases apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.009322

Norsolorinic acid inhibits proliferation of T24 human bladder cancer cells by arresting the cell cycle at the G0/G1 phase and inducing a Fas/membrane-bound Fas ligand-mediated apoptotic pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.009322

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.009322

Regulation of p53 downstream genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.009322

P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.009322

New cisplatin analogues in development. A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.009322

Disruption of p53 in human cancer cells alters the responses to therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.009322

Cisplatin-induced genes as potential markers for thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.009322

Unraveling the mechanism of radiosensitization by gemcitabine: the role of TP53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.009322

Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine).

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.009322

Evidence against apoptosis as a major mechanism for reproductive cell death following treatment of cell lines with anti-cancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.009322

Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.009322

P53 in bladder cancer: mechanism of action, prognostic value, and target for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.009322

Cross-linking of Complementary Strands of DNA in Mammalian Cells by Antitumour Platinum Compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FEBM.2010.009322

21 January 2018

Identifiers

DOI

10.1258/EBM.2010.009322

1 reference

14 September 2017

1 reference